Navigation Links
Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update

FORT WORTH, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced that it has filed it Q3 2009 financial results and has provided a comprehensive management business update to illustrate the developments during the 2009 calendar year.

  • Q3 2009 sales increased 33.5% to $102,926 vs. Q3 2008 sales of $77,084.
  • Shareholder equity as of the Q3 2009 increased to $3,327,892 vs. Q3 2008 shareholder equity of $(321,257)
  • Total assets increased to $4,934,524 in Q3 2009 vs. $151,714 in Q4 2008 while liabilities during the same period only increased 1,606,632 vs. 472,971 during the respective period.

A complete copy of the Company's Q3 2009 quarterly report that is filed with the SEC can be viewed at:

During the first three quarters of 2009, the Company's efforts where focused on increasing its distribution capabilities, expanding the market visibility of its signature product CellerateRx® and increasing its product portfolio. The outline below provides detailed breakdown of such achievements by the Company during this period of time.

Sales Distribution Agreements

"Over the past year we have been achieving milestones to take The Company to the next level. We have recently assembled a national sales force of over 40 independent representatives in addition to our extensive international distribution channel," stated CEO Scott Haire. "The third quarter 2009 numbers show that our efforts are beginning to pay off; our next benchmark is to become profitable in 2010 and bring earnings to the bottom line as quickly as possible, we expect to see a substantial increase in sales in the coming year as a direct result of the representatives having now completed their training."

During the past nine months the Company has significantly expanded its distribution capabilities through the signing of the following agreements and relationships:

  • Biocure S.r.l. of Milan, Italy, upon obtaining a CE market for Europe, will initially target over 1.5 million diabetic patients within its customer base in England, Italy, France, Germany and Spain alone, without factoring in the request for burn treatment which has been very strong.
  • Med Pro Associates of Colorado will serve as an independent sales and marketing representative to solicit sales, obtain orders and provide sales and marketing support for the company's line of products within the U.S. The agreement enables Med Pro to offer CellerateRx and other products to hospitals and doctors' offices in all 50 states.
  • Pharma Technology International, LLC will market, distribute and sell the company's wound care products in the Middle East, a market with a high degree of diabetic patients.

Independent Evidence Based Studies

"Several independently run evidence-based studies have reinforced our product's value, and the overwhelmingly positive data can now be accessed at," said Cathy Bradshaw, President of Wound Care Innovations, the division that markets CellerateRx. "Those of us with a relative or loved one that faces a diabetic wound induced limb amputation understand the value of our Company's unique core product which addresses a five billion dollar worldwide market."

Below is a subset of the recent conferences and studies that have been completed:

  • The clinical study, "Activated Collagen Accelerates Wound Repair and Modulates Cytokine Production in Whole Blood and PBMC Cultures" was presented at the Tri-Society Annual Conference 2009 of the Society for Leukocyte Biology, International Cytokine Society, & International Society for Interferon and Cytokine Research, Cellular and Cytokine Interactions in Health and Disease in Lisbon, Portugal, October 18-21, 2009, by authors Gregory B. Pott, K. Scott Beard, and Leland Shapiro, of the Department of Medicine, University of Colorado Denver, Aurora, Colorado and included data of patients with lower extremity diabetic ulcers by Matthew Regulski, Wound Care Center of Ocean County, New Jersey.
  • Dr. Jane Fore MD, FAPWCA, FACCWS, of the Tri-State Wound Care and Hyperbaric Center in Clarkston, WA, presented the results of her clinical study that showed that the use of hydrolyzed collagen (CellerateRx) increased the efficiency of healing in skin tears/flaps at the 24th Annual Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing, on October 22 in San Antonio.
  • The Company participated in the Save A Leg, Save a Life Foundation National Conference (SALSAL) in Orlando on October 8th.
  • The Company exhibit at the Georgetown University Hospital's Team Approach to Diabetic Limb Salvage (DLS) conference in Washington, D.C. on September 24th-26th. CellerateRx®, was featured in an abstract by Dr. Matthew Regulski, DPM, Director of the Wound Care Center of Ocean County, NJ. The abstract, "Activated Collagen: An Evidence Based Study in Human Leg Ulcers", provides data showing that all activated collagen treated wounds were healed by five weeks, while the control wounds were approximately 80% healed within twelve weeks.


The Company has completed acquisitions that have enhanced the current and future fundamental value of the Company. Below is a list of a few of the acquisitions that have been announced and are in the process of monetization.

  • Acquired Resorbable Orthopedics LLC, a private company, in an equity transaction. Through the acquisition the Company acquired patented technologies including a resorbable bone wax and a delivery system for orthopedic bone void fillers, among others.
  • Acquired BioPharma Management Technologies, Inc., a privately held biotechnology company, in an equity transaction. Through the acquisition the Company increased its platform of proprietary and patented technologies focused on the topical pain management and resorbable orthoses marketplace.

Technology Incubator Program

The Company announced that its BioPharma Management division expects to release news concerning its Technology Incubator Program shortly. The Company is in conversions with potential partners that can significantly advance the value of our technology relationships (including its license with VirtualHealth Technologies, Inc. for its Cifra secure healthcare platform) and other partnerships that have been previously announced.

With a synergistic focus on diabetic community the Company believes it is well positioned to provide further value to the medical community through its suite of technology relationships while further enhancing the fundamental value of the Company.

Public Company and Market Exposure Advancements

The Company is focused on increasing the market visibility and market exposure of the Company. With the achievements the Company has demonstrated over the last nine months and the goals that the company has set for 2010 we believe it would be a solid time to increase the exposure within the public markets. The increase in shareholder's equity was a major step forward in meeting the necessary requirement for listing on a national exchange during 2010, which the Company plans to work towards.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene (CELG), Geron (GERN), and Human Genome Sciences (HGSI) by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. For more information on the Company please visit or call our shareholder information department at 954-357-0614.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

SOURCE Wound Management Technologies, Inc.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds The Future of the Wound Care Management Market to 2015
2. Filtrona Porous Technologies Realizes Innovative New Product Development Through Foam-Fiber Technology Synergy : Introducing MediSponge(R) RBR Wound Care Dressings
3. Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded
4. Wound Management Technologies (OTCBB- WNDM) Signs Biotech Agreement With Biocure S.r.l. of Milan, Italy
5. Derma Sciences Announces Multiple Clinical Presentations of MEDIHONEY(R) at Upcoming Major Wound Care Conference
6. Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference
7. Wound Management Technologies Acquires Resorbable Orthopedics
8. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
9. New Data Supports ConvaTec Negative Pressure Wound Therapy
10. New Powder Speeds Healing of Difficult Foot Wounds
11. Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R)
Post Your Comments:
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):